(OFIX) Orthofix Medical - Overview

Sector: HealthcareIndustry: Medical Devices | Exchange NASDAQ (USA) | Currency USD | Market Cap: 468m | Total Return -28.8% in 12m

Stock: Spine Implants, Bone Growth, Limb Reconstruction, Navigation

Total Rating 33
Risk 43
Buy Signal -1.02
Medical Devices -2.7
Health Care Equipment -0.4
Market Cap: 468m
Avg Trading Vol: 3.64M USD
ATR: 4.12%
Peers RS (IBD): 28.3
Risk 5d forecast
Volatility 38.3%
Relative Tail Risk -6.29%
Reward TTM
Sharpe Ratio -0.79
Alpha -40.28
Character TTM
Beta 0.778
Beta Downside 1.106
Drawdowns 3y
Max DD 54.63%
CAGR/Max DD -0.22

EPS (Earnings per Share)

EPS (Earnings per Share) of OFIX over the last years for every Quarter: "2021-03": 0.17, "2021-06": 0.32, "2021-09": 0.1, "2021-12": 0.27, "2022-03": -0.1, "2022-06": 0.08, "2022-09": 0.13, "2022-12": 0.19, "2023-03": -0.1, "2023-06": 0.02, "2023-09": 0.07, "2023-12": 0.02, "2024-03": 0.11, "2024-06": 0.05, "2024-09": 0.07, "2024-12": 0.0154, "2025-03": -1.3549, "2025-06": -0.36, "2025-09": -0.57, "2025-12": 0.2378,
EPS CAGR: 6.52%
EPS Trend: -39.2%
Last SUE: 0.97
Qual. Beats: 1

Revenue

Revenue of OFIX over the last years for every Quarter: 2021-03: 105.593, 2021-06: 121.394, 2021-09: 112.428, 2021-12: 125.064, 2022-03: 106.418, 2022-06: 118.07, 2022-09: 113.996, 2022-12: 122.229, 2023-03: 175.204, 2023-06: 187.016, 2023-09: 184.006, 2023-12: 200.415, 2024-03: 188.608, 2024-06: 198.62, 2024-09: 196.606, 2024-12: 215.657, 2025-03: 193.646, 2025-06: 203.121, 2025-09: 205.634, 2025-12: 219.911,
Rev. CAGR: 21.36%
Rev. Trend: 85.5%
Last SUE: 3.24
Qual. Beats: 5

Description: OFIX Orthofix Medical March 05, 2026

Orthofix Medical Inc. (OFIX) is a medical technology company operating globally, with headquarters in Lewisville, Texas. The company was founded in 1980.

OFIX operates in two primary segments: Global Spine and Global Limb Reconstruction. The Global Spine segment focuses on bone growth stimulation devices, spinal fixation implants, and bone graft substitutes. This segment also develops navigation technologies for spinal and cranial procedures, including the 7D FLASH Navigation System. The medical device industry often sees innovation in surgical navigation for improved precision.

The Global Limb Reconstruction segment provides products and solutions for deformity correction, limb lengthening, and complex fracture management. This includes external and internal fixation devices, often integrated with digital technologies for patient care. The company distributes its products through a combination of distributors and sales representatives to various healthcare entities.

Further research on ValueRay can provide detailed financial metrics and competitive analysis for OFIX.

Headlines to watch out for

  • Spine and limb reconstruction product sales drive revenue
  • Regulatory approvals impact new product launches
  • Healthcare spending trends affect device demand
  • Competition from larger medical device companies
  • Supply chain disruptions increase production costs

Piotroski VR‑10 (Strict, 0-10) 5.5

Net Income: -92.2m TTM > 0 and > 6% of Revenue
FCF/TA: -0.00 > 0.02 and ΔFCF/TA 0.96 > 1.0
NWC/Revenue: 29.96% < 20% (prev 33.10%; Δ -3.14% < -1%)
CFO/TA 0.04 > 3% & CFO 34.1m > Net Income -92.2m
Net Debt (147.2m) to EBITDA (84.2m): 1.75 < 3
Current Ratio: 2.45 > 1.5 & < 3
Outstanding Shares: last quarter (40.0m) vs 12m ago 3.36% < -2%
Gross Margin: 67.09% > 18% (prev 0.68%; Δ 6.64k% > 0.5%)
Asset Turnover: 94.31% > 50% (prev 89.50%; Δ 4.81% > 0%)
Interest Coverage Ratio: -4.19 > 6 (EBITDA TTM 84.2m / Interest Expense TTM 17.5m)

Altman Z'' -1.03

A: 0.29 (Total Current Assets 416.8m - Total Current Liabilities 170.5m) / Total Assets 850.6m
B: -0.43 (Retained Earnings -368.3m / Total Assets 850.6m)
C: -0.08 (EBIT TTM -73.3m / Avg Total Assets 872.0m)
D: -0.91 (Book Value of Equity -363.7m / Total Liabilities 400.6m)
Altman-Z'' Score: -1.03 = CCC

Beneish M -3.16

DSRI: 0.98 (Receivables 135.7m/134.7m, Revenue 822.3m/799.5m)
GMI: 1.02 (GM 67.09% / 68.28%)
AQI: 1.00 (AQ_t 0.36 / AQ_t-1 0.36)
SGI: 1.03 (Revenue 822.3m / 799.5m)
TATA: -0.15 (NI -92.2m - CFO 34.1m) / TA 850.6m)
Beneish M-Score: -3.16 (Cap -4..+1) = AA

What is the price of OFIX shares?

As of March 29, 2026, the stock is trading at USD 11.50 with a total of 240,203 shares traded.
Over the past week, the price has changed by -1.29%, over one month by -15.00%, over three months by -25.71% and over the past year by -28.84%.

Is OFIX a buy, sell or hold?

Orthofix Medical has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy OFIX.
  • StrongBuy: 2
  • Buy: 1
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the OFIX price?

Issuer Target Up/Down from current
Wallstreet Target Price 17.3 50%
Analysts Target Price 17.3 50%

OFIX Fundamental Data Overview March 29, 2026

P/E Forward = 37.8788
P/S = 0.5687
P/B = 1.0392
P/EG = 3.7905
Revenue TTM = 822.3m USD
EBIT TTM = -73.3m USD
EBITDA TTM = 84.2m USD
Long Term Debt = 157.4m USD (from longTermDebt, last quarter)
Short Term Debt = 3.98m USD (from shortTermDebt, last quarter)
Debt = 229.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 147.2m USD (from netDebt column, last quarter)
Enterprise Value = 614.9m USD (467.7m + Debt 229.3m - CCE 82.0m)
Interest Coverage Ratio = -4.19 (Ebit TTM -73.3m / Interest Expense TTM 17.5m)
EV/FCF = -1000.0x (Enterprise Value 614.9m / FCF TTM -485k)
FCF Yield = -0.08% (FCF TTM -485k / Enterprise Value 614.9m)
FCF Margin = -0.06% (FCF TTM -485k / Revenue TTM 822.3m)
Net Margin = -11.21% (Net Income TTM -92.2m / Revenue TTM 822.3m)
Gross Margin = 67.09% ((Revenue TTM 822.3m - Cost of Revenue TTM 270.6m) / Revenue TTM)
Gross Margin QoQ = 64.59% (prev 72.23%)
Tobins Q-Ratio = 0.72 (Enterprise Value 614.9m / Total Assets 850.6m)
Interest Expense / Debt = 1.90% (Interest Expense 4.35m / Debt 229.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -57.9m (EBIT -73.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.45 (Total Current Assets 416.8m / Total Current Liabilities 170.5m)
Debt / Equity = 0.51 (Debt 229.3m / totalStockholderEquity, last quarter 450.0m)
Debt / EBITDA = 1.75 (Net Debt 147.2m / EBITDA 84.2m)
Debt / FCF = -303.5 (out of range, set to none) (Net Debt 147.2m / FCF TTM -485k)
Total Stockholder Equity = 452.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.57% (Net Income -92.2m / Total Assets 850.6m)
RoE = -20.38% (Net Income TTM -92.2m / Total Stockholder Equity 452.3m)
RoCE = -12.03% (EBIT -73.3m / Capital Employed (Equity 452.3m + L.T.Debt 157.4m))
RoIC = -9.50% (negative operating profit) (NOPAT -57.9m / Invested Capital 609.4m)
WACC = 6.34% (E(467.7m)/V(696.9m) * Re(8.72%) + D(229.3m)/V(696.9m) * Rd(1.90%) * (1-Tc(0.21)))
Discount Rate = 8.72% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 3.65%
[DCF] Fair Price = unknown (Cash Flow -485k)
EPS Correlation: -39.24 | EPS CAGR: 6.52% | SUE: 0.97 | # QB: 1
Revenue Correlation: 85.49 | Revenue CAGR: 21.36% | SUE: 3.24 | # QB: 5
EPS current Year (2026-12-31): EPS=0.15 | Chg7d=-0.535 | Chg30d=-0.270 | Revisions Net=+0 | Growth EPS=-69.2% | Growth Revenue=+4.1%
EPS next Year (2027-12-31): EPS=0.85 | Chg7d=-0.205 | Chg30d=+0.035 | Revisions Net=+0 | Growth EPS=+470.0% | Growth Revenue=+6.2%

Additional Sources for OFIX Stock

Fund Manager Positions: Dataroma | Stockcircle